Medical Health & Life Science Research News

Research report explores the adult vaccines market global trends and forecasts to 2020

Medical Market Research

Global - Adult Vaccines Market and Company Analysis to 2020 is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

- Advertising -

Complete report available at

Adults are as likely as children to die from diseases that they can be immunized.

- Advertising -

For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly.

Adult vaccines continues to be one of the growing segment for pharmaceutical companies.

The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 7% over the next five years. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines.

The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines are the most popular and accepted vaccination amongst adults. It accounted for maximum share of adult vaccines market in 2014.

The vaccinations for hepatitis is the second most popular vaccines in 2014. The HPV/Cervical cancer vaccines and pneumococcal vaccines stands at third and fourth spots respectively in adult vaccines market.

While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.

Access a copy of this “Global Adult Vaccines Market” research report at…e.php?name=481207.

Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquires Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second spot in the adult vaccines market.

GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer and Novartis is at the fourth and fifth position respectively in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales.

Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in influenza vaccine landscape, while in the cervical cancer market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japan adult vaccines market share is expected to remain flat during the forecasting period.

South America and India are competing closely with each other to get the maximum share of the adult vaccines market pie.

News From

MarketReportsOnline - Industry Research Analysis StoreMarketReportsOnline
Category: Market Research Publishers and RetailersCompany about: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.